Edwin A. Basak

542 citations

18 papers · 403 indexed · h-index 10

Oncology top 10%
- Cancer Immunotherapy and Biomarkers 16
- CAR-T cell therapy research 4
- Pancreatic and Hepatic Oncology Research 3
- Colorectal Cancer Treatments and Studies 3
- Cancer Diagnosis and Treatment 2
Immunology
- Immunotherapy and Immune Responses 3
Complementary and Manual Therapy top 10%
Cancer Research
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 3
Epidemiology
- Neuroendocrine Tumor Research Advances 2

Co-authors: Stijn L.W. Koolen Ron H.J. Mathijssen Joachim G.J.V. Aerts Reno Debets Astrid A.M. van der Veldt Sander Bins Daan P. Hurkmans Esther Oomen‐de Hoop
Cited by: Oncology Immunology Complementary and Manual Therapy
Journals: Journal for ImmunoTherapy of Cancer (4 papers)Annals of Oncology (4 papers)Journal of Clinical Oncology (2 papers)
Partner nations: Netherlands Switzerland Chile

In The Last Decade

Edwin A. Basak

17 papers receiving 400 citations

Peers

Countries citing papers authored by Edwin A. Basak

Since Specialization

Citations

This map shows the geographic impact of Edwin A. Basak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edwin A. Basak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edwin A. Basak more than expected).

Fields of papers citing papers by Edwin A. Basak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edwin A. Basak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edwin A. Basak. The network helps show where Edwin A. Basak may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Edwin A. Basak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Edwin A. Basak Line = papers co-authored together Edwin A. Basak links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors Cancer Treatment Reviews ·Karlijn de Joode,Hossein Farahini,Edwin A. Basak,Sander Bins,Astrid A.M. van der Veldt,Ron H. N. van Schaik,Ron H.J. Mathijssen	2023	2
2	Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study European Journal of Cancer ·Edwin A. Basak,電気学会絶縁材料耐トラッキング性調査専門委員会,Karlijn de Joode,Daan P. Hurkmans,SiYong Cheng,Esther Oomen‐de Hoop,Marco W.J. Schreurs,Sander Bins,Stijn L.W. Koolen,Reno Debets,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Arjen Joosse,Ron H.J. Mathijssen	2022	13
3	The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy Biomedicine & Pharmacotherapy ·Edwin A. Basak,Karlijn de Joode,蔡中川,I.S Kim,Marco W.J. Schreurs,Sjoerd A.A. van den Berg,Esther Oomen‐de Hoop,Cor H. van der Leest,Layal Chaker,Richard A. Feelders,Astrid A.M. van der Veldt,Arjen Joosse,Stijn L.W. Koolen,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Sander Bins	2022	4
4	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Nicole Ó Catháin,Karlijn de Joode,A. Scholenberger,Edwin A. Basak,Annemarie Wijkhuijs,Markus Joerger,Reno Debets,Birgit C. P. Koch,Cor H. van der Leest,Marco W.J. Schreurs,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2021	15
5	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients Thyroid ·Edwin A. Basak,R.H. Dee,Daan P. Hurkmans,Marco W.J. Schreurs,Esther Oomen‐de Hoop,Astrid A.M. van der Veldt,Sander Bins,Arjen Joosse,Stijn L.W. Koolen,Reno Debets,Robin P. Peeters,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Marco Medici	2020	64
6	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Edwin A. Basak,José Julián Echeverry,Esther Oomen‐de Hoop,Cor H. van der Leest,Samira El Bouazzaoui,Sander Bins,Stijn L.W. Koolen,Stefan Sleijfer,Astrid A.M. van der Veldt,Reno Debets,Ron H. N. van Schaik,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2020	51
7	Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer European Journal of Cancer ·Edwin A. Basak,Stijn L.W. Koolen,Daan P. Hurkmans,Marco W.J. Schreurs,Sander Bins,Esther Oomen‐de Hoop,Annemarie Wijkhuijs,Suresh Kommu,Stefan Sleijfer,Reno Debets,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2019	54
8	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Edwin A. Basak,N. Ba-Diop,João Eudes Bezerra Filho,Marco W.J. Schreurs,Annemarie Wijkhuijs,Sander Bins,Esther Oomen‐de Hoop,Reno Debets,Markus Joerger,Arlette E. Odink,Astrid A.M. van der Veldt,Cor H. van der Leest,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2019	66
9	CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab Journal for ImmunoTherapy of Cancer ·André Kunert,Edwin A. Basak,Daan P. Hurkmans,Hayri E. Balcıoğlu,Yarne Klaver,Mandy van Brakel,郭宥均,C. B. H. W. Lamers,Sander Bins,Stijn L.W. Koolen,Astrid A.M. van der Veldt,Stefan Sleijfer,Ron H.J. Mathijssen,Joachim G.J.V. Aerts,Reno Debets	2019	43
10	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients Annals of Oncology ·Daan P. Hurkmans,Edwin A. Basak,Emmalee Mangum,João Eudes Bezerra Filho,Marco W.J. Schreurs,Annemarie Wijkhuijs,Sander Bins,Esther Oomen‐de Hoop,Reno Debets,Markus Joerger,Arlette E. Odink,Astrid A.M. van der Veldt,Cor H. van der Leest,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2019	2
11	Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy Annals of Oncology ·M Boucard,Edwin A. Basak,Daan P. Hurkmans,Marco W.J. Schreurs,Esther Oomen‐de Hoop,Astrid A.M. van der Veldt,Sander Bins,Arjen Joosse,Stijn L.W. Koolen,Reno Debets,Robin P. Peeters,Vipan Kuamr,Ron H.J. Mathijssen,Marco Medici	2019	0
12	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients British Journal of Cancer ·Sander Bins,Edwin A. Basak,Samira El Bouazzaoui,Stijn L.W. Koolen,Esther Oomen‐de Hoop,Cor H. van der Leest,Astrid A.M. van der Veldt,Stefan Sleijfer,Reno Debets,Ron H. N. van Schaik,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2018	52
13	Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma. Journal of Clinical Oncology ·Daan P. Hurkmans,Els M.E. Verdegaal,Sabrina A. Hogan,Edwin A. Basak,Dianne M.A. van den Heuvel,Rik de Wijn,Rob Ruijtenbeek,John P. Groten,Reinhard Dummer,Stijn L.W. Koolen,Marij J.P. Welters,Ron H.J. Mathijssen,Ellen Kapiteijn,Joachim G.J.V. Aerts,Mitchell P. Levesque,Sjoerd H. van der Burg	2018	1
14	Development of an Enzyme-Linked Immune Sorbent Assay to Measure Nivolumab and Pembrolizumab Serum Concentrations Therapeutic Drug Monitoring ·Edwin A. Basak,Annemarie Wijkhuijs,Ron H.J. Mathijssen,Stijn L.W. Koolen,Marco W.J. Schreurs	2018	17
15	Correlation between nivolumab exposure and treatment outcome in NSCLC. Journal of Clinical Oncology ·Stijn L.W. Koolen,Edwin A. Basak,Daan P. Hurkmans,Marco W.J. Schreurs,Sander Bins,Esther Oomen‐de Hoop,Reina Duran,Suresh Kommu,Stefan Sleijfer,Reno Debets,А. Ю. Борисов,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2018	2
16	Association of single nucleotide polymorphisms with efficacy in nivolumab-treated NSCLC patients Annals of Oncology ·Edwin A. Basak,Sander Bins,Samira El Bouazzaoui,Stijn L.W. Koolen,Esther Oomen‐de Hoop,Cor van der Leest,Astrid A.M. van der Veldt,Stefan Sleijfer,Reno Debets,Ron H. N. van Schaik,Ron H.J. Mathijssen,Joachim G.J.V. Aerts	2017	1
17	Association between single nucleotide polymorphisms and side effects in nivolumab treated NSCLC patients Annals of Oncology ·Sander Bins,Edwin A. Basak,Samira El Bouazzaoui,Stijn L.W. Koolen,Cor van der Leest,Stefan Sleijfer,Reno Debets,Ron H. N. van Schaik,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2016	1
18	Effects of thermal sulphur bath cure on adjuvant arthritic rats Physikalische Medizin Rehabilitationsmedizin Kurortmedizin ·Mine Karagülle,Rina Marlena,P.G. Yakovenko,Edwin A. Basak,Mayur Godse	1996	15

About Edwin A. Basak

Edwin A. Basak is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 18 papers that have together received 403 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Immunotherapy and Immune Responses (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Lung Cancer Treatments and Mutations (3 papers), Neuroendocrine Tumor Research Advances (2 papers) and Cancer Diagnosis and Treatment (2 papers). The work is most often cited by research in Oncology (318 citations), Immunology (126 citations) and Complementary and Manual Therapy (11 citations). Edwin A. Basak has collaborated with scholars based in Netherlands, Switzerland and Chile. Frequent co-authors include Stijn L.W. Koolen, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Reno Debets, Astrid A.M. van der Veldt, Sander Bins, Daan P. Hurkmans, Esther Oomen‐de Hoop, Marco W.J. Schreurs and Stefan Sleijfer. Their work appears in journals such as Journal for ImmunoTherapy of Cancer, Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact